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Cell adhesion molecules (CAMs) are a group of cell
surface molecules capable of binding leukocytes
through specific counter-receptors. CAMs are members
of the large immunoglobulin superfamily by virtue of
their extracellular immunoglobulin-like domains, and
are expressed in the kidney in endothelial cells, mesang-
ial cells, and renal tubular epithelial cells (TEC) [1].
Table 1 summarizes the characteristics of two major
renal CAMs, ICAM-1 and VCAM-1. Intercellular
adhesion molecule-1 (ICAM-1) is a monomeric
unpaired cell-surface glycoprotein of 76—114 kDa, and
is found in many different cell types in various tissues.
Vascular cell adhesion molecule-1 (VCAM-1) is an
inducible monomeric cell-surface glycoprotein of
110 kDa which is not only expressed on vascular
endothelium as its name implies, but also on extravas-
cular sites such as mesangial cells and TEC.
ICAM-1 and VCAM-1 are induced in the kidney in
immunologically mediated renal diseases. This induc-
tion is caused by interferons and certain cytokines,
namely TNF-a and IL-1. Cytomegalovirus is also able
to enhance directly ICAM-1 expression on cultured
proximal TEC [2], and perhaps also in vivo.
The expression of ICAM-1 is enhanced in various
inflammatory renal disease states, and it has been
speculated that upregulation of CAMs confers
increased 'stickiness' to the kidney, thereby promoting
leukocyte-mediated renal injury [3]. In human renal
allograft rejection, ICAM-1 expression is prominent
on renal TEC [4,5], paralleling MHC class II expres-
sion [6]. Increased glomerular ICAM-1 expression can
be demonstrated in rapidly progressive glomerulo-
nephritis, lupus nephritis and some other glomeru-
Table 1. Characteristics of the cell adhesion molecules ICAM-1
and VCAM-1
Molecule ICAM-1 VCAM-1
Ig-like domains
Conter-receptor
Inducing cytokines
Chromosomal location
5
LFA-1
Mac-1
CD43
TNF-a, IL-1
IFN-y
19
7, 6 or 3
VLA^
TNF-a, IL-1
IFN-y
1
lonephritides [7]. The enhanced glomerular ICAM-1
expression in these diseases is sometimes accompanied
by increased tubular ICAM-1 staining at the luminal
side. The increased tubular ICAM-1 expression correl-
ates with the presence of LFA-1 positive intratubular
leukocytes [7]. VCAM-1 expression is also enhanced
in inflammatory renal diseases, including crescentic
nephritis, vasculitis, interstitial nephritis, and allograft
rejection [8,9]. Up-regulation of VCAM-1 is particu-
larly striking in proximal TEC and endothelial cells.
In our own studies we investigated ICAM-1 and
VCAM-1 expression in murine models of autoimmune
renal injury and found that CAMs are up-regulated in
the kidney of MRL/lpr and (NZBxNZW^ mice with
lupus nephritis [3,10]. Low constitutive expression is
found in normal mice in glomeruli and proximal
tubules. Up-regulation in autoimmune strains is par-
ticularly prominent in proximal tubules, endothelium
and mesangial cells. TNF-a and IL-1 are present at
high levels in the kidneys of autoimmune MRL/lpr
and (NZBxNZW)F! mice [11,12], and could be dir-
ectly responsible for the increased expression of
ICAM-1 and VCAM-1 in the kidney of these auto-
immune strains.
In vitro we have demonstrated that ICAM-1 and
VCAM-1 are rapidly induced in cultured TEC in
response to TNF-a, IL-1 and IFN-y [10,13]. Peak
expression occurs within 6 h, and involves translation
of mRNA and de-novo transcription. It also appears
that a down-regulation-resistant type of protein kinase
C is involved in the induction in response to the
cytokines TNF-a and IL-1 [14,15]. Commonly used
immunosuppressants such as cyclosporin A, steroids
and azathioprine are unable to block the cytokine-
induced expression of ICAM-1 and VCAM-1 in vitro;
this does not exclude an inhibitory effect in vivo through
reduced expression of cytokines [16].
Cytokine-stimulated monolayers of TEC become
more adhesive for leukocytes (T cells, monocytic cells).
This adherence can be blocked with monoclonal anti-
bodies (MAb) targeting ICAM-1 and VCAM-1, and
also by blocking the counter-receptors LFA-1 and
VLA-4 respectively. Antigen presentation by TEC can
also be inhibited with anti-ICAM-1 and anti-LFA-1
monoclonal antibody treatment in vitro [13]. Others
have shown that the cytotoxic action of T cells for
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TEC can be inhibited with anti-ICAM-1/anti-LFA-l
MAb [17]. Thus, TEC expression of adhesion molec-
ules such as ICAM-1 confers enhanced stickiness and
immune reactivity for T cells, and may therefore pro-
mote immune renal injury.
What is the in-vivo significance of these inducible
CAMs in renal injury? Certain CAMs have a well-
known structural (architectural) function in the kidney
in that they play an essential role in cell-cell contact.
Thus, NCAM (neural cell adhesion molecule) is a
Ca2+-independent cell-cell adhesion molecule member
of the immunoglobulin superfamily that causes renal
tubular cell binding through homophilic interaction
among NCAM molecules [18]. Cadherins such as
uvomorulin (E-cadherin) and N-cadherin are Ca2+-
dependent CAMs with structural function and cell-
polarity-inducing characteristics in the kidney [19].
Both NCAM and the cadherins also play an important
role in morphogenesis and nephron development.
CD31 (also termed PECAM-1), a 6 Ig extracellular
domain member of the immunoglobulin superfamily,
is another example of a CAM that is capable of
homophilic (and possibly heterophilic) cell-cell inter-
action in the kidney [20], thus playing a role in kidney
structure.
ICAM-1 and VCAM-1, however, do not appear to
have primarily a structural function. We have shown
that kidney cryostat section from MRL/lpr mice dis-
play a significant increase in the adherence for T cells
and monocytes when compared with sections obtained
from normal mice [3]. This adherence can be blocked
to various degrees with antibodies targeting ICAM-1
or VCAM-1. These experiments directly demonstrate
that the kidney parenchyma becomes more sticky for
inflammatory cells in murine autoimmune renal dis-
ease, and that this enhanced stickiness is caused pre-
dominantly by ICAM-1 and VCAM-1.
Several MAb against different adhesion molecules
have been tested for therapeutic intervention in experi-
mental models of renal inflammation. Anti-ICAM-1
and anti-LFA-1 MAb have already been tried in human
kidney allograft rejection.
A murine anti-human ICAM-1 MAb (R6.5) has
been used both prophylactically and therapeutically in
Cynomolgus monkeys receiving kidney allografts [21].
While this monoclonal antibody clearly prolongs car-
diac and renal allograft survival in Cynomolgus mon-
keys, its clinical usefulness needs to be confirmed. A
small human trial using the same ICAM-1 antibody
(BIRR1, previously termed R6.5) showed limited use-
fulness in controlling allograft rejection and possibly
reperfusion injury [22]. An anti-LFA-1 antibody used
in a small clinical trial to treat acute renal transplant
rejection showed no effectiveness [23].
A recent study using mouse heart allografts nicely
demonstrated that tolerance could be induced against
major histocompatibility barriers when anti-ICAM-1
and anti-LFA-1 monoclonal antibodies were used
together [24]. Although the mechanisms of tolerance
induction in this animal model remain to be deter-
mined, this promising study may have important con-
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sequences for prevention and treatment of human renal
allograft rejection.
In a recent study of hereditary autoimmune tubulo-
interstitial nephritis in the mouse (kdkd mouse of the
CBA/Ca strain) it was shown that ICAM-1 is overex-
pressed in the kidney of these mice with interstitial
nephritis [25]. Treatment with an anti-ICAM-1 MAb
reduced the leukocyte infiltration, and also reduced
proteinuria. In rat models of nephrotoxic serum neph-
ritis and crescentic glomerulonephritis it could be
shown that treatment with anti-ICAM-1 or anti-LFA-1
MAb reduced proteinuria and glomerular inflamma-
tion [26-28].
In summary, the cell adhesion molecules ICAM-1
and VCAM-1 play an important role in immune-
mediated renal diseases. By conferring increased adhes-
iveness to the renal parenchyma they promote the
adhesion of inflammatory leukocytes. Targeting these
adhesion molecules with MAb may show promising
effects in various renal diseases and in allograft
rejection.
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